Germany’s hospital reform draft law on improving quality of care in the inpatient setting and reforming reimbursement structures was passed on second reading in the lower house of parliament on 17 October.
Germany’s Hospital And Reimbursement Reform Battles Into The Final Straight
‘Ampel’ Coalition Defends ‘Quality Not Quantity’ Bill In Parliamentary Plenary
“Flying blind” into healthcare reform was among the feisty criticisms of Germany’s proposed law on hospital care improvement during the final parliamentary plenary on 17 October. SPD health minister Karl Lauterbach has stoutly defended his reform.
More from Germany
• By
The IVD industry’s new 10-point plan for healthcare change shows that medtechs will keep calling the German government to account. Tariffs, sector resilience, digital functionality are among the pressing issues industry wants answers to.
• By
Whoever is handed the health portfolio in Germany’s new coalition government will face demands to amend the recently-enacted hospital and DRGs reform law. The medtech industry has been quick to make the case for change.
• By
Germany’s Union parties may have little alternative than to bring the SPD into a new four-year coalition, says Clifford Chance partner and life sciences legal expert Gunnar Sachs. Health policy will likely see both textural and structural changes.
• By
Germany’s government-industry healthcare industry roundtables have yielded a final report, even though the program was curtailed by the snap election. The new CDU-led government should pick up the baton, medtech industry associations say.
More from Policy & Regulation
• By
The Visby Medical Women’s Sexual Health Test is the first over-the-counter test cleared by the US Food and Drug Administration to detect chlamydia, gonorrhea and trichomoniasis. It delivers results in about 30 minutes.
• By
A federal judge in Texas delivered what is most likely a fatal blow to the US FDA’s final rule, which would have regulated lab-developed tests as medical devices.
• By
Cybersecurity, sustainability and regulatory intelligence all need factoring into risk management today as AI and data availability change the goalposts. Eight experts tell Medtech Insight how compliance efforts must adapt.